U.S. Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Laboratory Tests, Imaging, Endoscopy, Biopsy), By End-use, By Region, And Segment Forecasts, 2024 - 2030

U.S. Liver Cancer Diagnostics Market Trends

The U.S. liver cancer diagnostics market size was estimated at USD 3.19 billion in 2023 and is projected to grow at a CAGR of 4.4% from 2024 to 2030. This growth is attributable to the increasing prevalence of liver cancer, rising initiatives undertaken by public and private organizations, increasing prevalence of risk factors for liver cancer, and technological advancements.

In the U.S., liver cancer is one of the leading causes of cancer-related deaths. The prevalence of liver and intrahepatic bile duct cancer in the U.S. is significant; over 41,000 new cases were expected to be diagnosed in 2023, affecting more men than women. The death rates from these cancers have also been rising, with over 29,000 deaths expected to be reported in the same year. Liver cancer incidence rates have more than tripled since 1980, while death rates have more than doubled during this time.

During the COVID-19 pandemic, the focus on disease management and health surveillance intensified, increasing the demand for rapid screening methods and point-of-care tests to combat outbreaks effectively. However, the impact of the pandemic on cancer care has been significant, with resources and funds being redirected towards COVID-19 response efforts, causing disruptions in cancer care services. For instance, during the early months of the pandemic, many liver cancer screening programs were canceled in a majority of healthcare centers, leading to delays in treatments for patients. This disruption highlighted the need to reassess and prioritize cancer care services amidst public health emergencies.

The risk factors associated with liver cancer include chronic alcohol consumption, Hepatitis B, Hepatitis C, non-alcoholic fatty liver disease, obesity, diabetes mellitus, aflatoxin exposure, smoking, and certain rare diseases like tyrosinemia, alpha1-antitrypsin deficiency, Porphyria cutanea tarda, glycogen storage diseases, and Wilson disease. These factors can significantly increase the chances of developing hepatocellular carcinoma (HCC), with chronic viral hepatitis being one of the most common risk factors. Additionally, environmental factors like exposure to certain chemicals and aflatoxin, as well as lifestyle factors such as body weight, smoking, and alcohol consumption, play crucial roles in the development of liver cancer.

Market Concentration & Characteristics

Market growth stage is medium and the pace of industry growth is accelerating. The focus on various innovative technologies to improve early detection rates and treatment outcomes accelerates industry growth. Some prominent advancements include liquid biopsy tests, genomic profiling, and advanced imaging technologies. Additionally, the use of Artificial Intelligence (AI) has revolutionized the liver cancer diagnostics market.

AI algorithms are being utilized to analyze imaging data and assist in the early detection of liver cancer through pattern recognition and data analysis. These innovations collectively hold great promise for enhancing early detection rates, improving treatment outcomes, and ultimately extending the survival of patients with liver cancer by enabling more precise and timely interventions based on individualized risk profiles and tumor characteristics.

Mergers and acquisitions (M&A) in the healthcare industry, including companies that focus on liver cancer diagnosis, have been increasing in recent years. These activities are driven by various factors, such as the need to expand product offerings, access new markets, and acquire new technologies. For example, in March 2019, Guardant Health, a liquid biopsy company, acquired Bellwether Bio to expand its product portfolio and strengthen its position in the precision oncology market.

Companies operating in the liver cancer diagnosis market are continuously expanding their product offerings to cater to various customer needs and preferences. This includes developing new diagnostic tests for different stages of liver cancer, as well as creating complementary products like data analysis tools and software platforms. For instance, Illumina’s TruSight Tumor 170 assay enables comprehensive genomic profiling of solid tumors, including liver cancer. Similarly, Thermo Fisher Scientific’s Oncomine Precision Assay provides a comprehensive panel of gene fusions, insertions/deletions (indels), and single nucleotide variants (SNVs) for solid tumors, enabling accurate identification of liver cancer subtypes.

Test Type Insights

The laboratory tests segment accounted for the largest revenue share of around 40% in 2023. Laboratory testing includes biomarker tests and blood tests. Biomarker tests play a crucial role in the detection and management of liver cancer. These tests involve analyzing specific molecules or substances in the blood that can indicate the presence of liver cancer or provide information about the progression of the disease. Common biomarkers in liver cancer detection include alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin (DCP), and glypican-3.

Several imaging techniques and blood tests are available for liver cancer screening, including ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and serum alpha-fetoprotein (AFP). These methods play a crucial role in the early detection of hepatocellular carcinoma (HCC), which is essential for initiating potentially curative therapies in the initial stages of the disease. Imaging ligands targeting glypican-3 receptor expression, such as peptides, antibodies, and aptamers, have shown promise for accurate diagnosis, staging, and prognosis of HCC.

End-use Insights

The hospitals and diagnostic laboratories segment dominated the market with a revenue share of around 50% in 2023. Hospitals are primary diagnosis centers, providing care, disease management, and treatment for various conditions like Hepatocellular Carcinoma (HCC), cholangiocarcinoma, and others. They offer facilities for long-term disease management and treatment, making them essential for patients requiring ongoing medical attention. Additionally, hospitals and diagnostic laboratories provide cost-effective screening products, enabling early detection and intervention. The presence of skilled healthcare professionals, advanced diagnostic techniques, sample collection capabilities, and highly sensitive data within hospital settings contributes to a short turnaround time for diagnosis and treatment

The pharmaceutical and Contract Research Organization (CRO) laboratories segment is expected to witness significant CAGR over the forecast period. This growth is attributed to their contribution to advancing cancer research, facilitating drug development, and contributing to the approval process for new treatments in oncology.

Key U.S. Liver Cancer Diagnostics Company Insights

Some of the key players operating in the U.S. market include Abbott Laboratories; Guardant Health; Thermo Fisher Scientific, Inc.; Illumina, Inc.; F. Hoffmann-La Roche Ltd.; and Qiagen N.V.

• Guardant Health is a pioneering company in the field of cancer diagnostics and treatment, specializing in liquid biopsy technologies that enable non-invasive detection, monitoring, and personalized treatment of various types of cancers.

• Illumina, Inc. offers a wide variety of sequencing and microarray products for cancer research. In addition to sequencing technologies, it provides microarray solutions that enable high-throughput analysis of genetic variations, gene expression patterns, and DNA methylation in cancer samples.

Siemens Healthineers; Becton, Dickinson & Company; Epigenomics AG; Koninklijke Philips N.V.; and FUJIFILM Healthcare Americas Corporation are some of the other market participants in the U.S. liver cancer diagnostics market.

Recent Developments

• In October 2023, Qiagen collaborated with Myriad Genetics to develop and commercialize laboratory-developed cancer test kits for the U.S. market.

• In December 2022, Integrated DNA Technologies (IDT) acquired ArcherDX's Next Generation Sequencing (NGS) research assays from Invitae Corporation, making a significant move in the genomics and molecular biology industry as IDT expanded its portfolio to include ArcherDX's innovative NGS technologies.

• In November 2019, Exact Sciences, a company specializing in cancer screening tests, acquired Genomic Health to broaden its offerings in comprehensive genomic profiling and expand its presence in the oncology market.

U.S. Liver Cancer Diagnostics Market Report Scope

U.S. Liver Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. liver cancer diagnostics market report based on test type, end-use, and region.

• Test Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Laboratory Tests

    • Biomarkers

      • Oncofetal and Glycoprotein Antigens

      • Enzymes and Isoenzymes

      • Growth Factors and Receptors

      • Molecular Markers

      • Pathological Biomarkers

    • Blood Tests

  • Imaging

  • Endoscopy

  • Biopsy

  • Others    

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals & Diagnostic Laboratories

  • Academic & Research Institutes

  • Pharmaceutical & CRO Laboratories

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • West

  • Midwest

  • Northeast

  • Southwest

  • Southeast